ASP Isotopes entered into supply agreement with Isotopia Molecular

ASP Isotopes (ASPI) announced that it has recently entered into a supply agreement with Isotopia Molecular Imaging Ltd. related to the supply of enriched Gadolinium-160, a critical precursor isotope for producing Terbium-161, an emerging medical isotope with significant potential in targeted radiotherapeutics. This agreement addresses longstanding supply challenges for Gd-160, enabling Isotopia to advance Tb-161-based therapies for prostate cancer, neuroendocrine tumours, and other malignancies. Under the agreement, ASP Isotopes will leverage its proprietary Quantum Enrichment technology to provide Isotopia with enriched Gd-160, a stable isotope essential for manufacturing Tb-161. The supply agreement is for four years’ supply, commencing in 2026, with an expected minimum contract value of $1 million per annum.